 |
Mubadala unit acquires Julphar subsidiaryKelix bio, wholly owned by Mubadala Investment Company, an Abu Dhabi sovereign investor, has completed the acquisition of DiabTec, a subsidiary of Julphar. This acquisition strengthens Mubadala's port More… |
|
Mubadala unit acquires Julphar subsidiaryKelix bio, wholly owned by Mubadala Investment Company, an Abu Dhabi sovereign investor, has completed the acquisition of DiabTec, a subsidiary of Julphar. This acquisition strengthens Mubadala's port More… |
 |
Julphar announces divestment from Zahrat Al RawdahGulf Pharmaceutical Industries (Julphar) has announced its divestment from Zahrat Al Rawdah Pharmacies, which will be taken over by BinDawood Holding for a total cash consideration of SR444.1 million ($118.25 million). More… |
|
Julphar announces divestment from Zahrat Al RawdahGulf Pharmaceutical Industries (Julphar) has announced its divestment from Zahrat Al Rawdah Pharmacies, which will be taken over by BinDawood Holding for a total cash consideration of SR444.1 million ($118.25 million). More… |
 |
Julphar reports 2.8% revenue growth in H1Gulf Pharmaceutical Industries (Julphar), a leading pharmaceutical powerhouse in the MENA region, reported robust sales growth during the first half of the year, driven by a particularly strong second quarter. More… |
 |
Julphar 9M revenues stable at $340mGulf Pharmaceutical Industries (Julphar), amid the current political headwinds and currency devaluation in Egypt, posted stable revenue of AED1.25 billion ($340 million) at constant currency in the first nine months (9M) of 2023. More… |
|
Julphar 9M revenues stable at $340mGulf Pharmaceutical Industries (Julphar), amid the current political headwinds and currency devaluation in Egypt, posted stable revenue of AED1.25 billion ($340 million) at constant currency in the first nine months (9M) of 2023. More… |
 |
Julphar's H1 net profit surges to $234m on solid GCC growthGulf Pharmaceutical Industries (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has reported revenues of AED859.4 million ($234 million) for the first half of 2023, registering a 2.5% increase year-on-y More… |
|
Julphar's H1 net profit surges to $234m on solid GCC growthGulf Pharmaceutical Industries (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has reported revenues of AED859.4 million ($234 million) for the first half of 2023, registering a 2.5% increase year-on-y More… |
 |
Increased revenues push up Julphar EBITDA by 13.5pcGulf Pharmaceutical Industries (Julphar), has seen EBITDA from continuing operations reaching AED45.4 million ($12.36 million) in Q1 2023 boosted by a 8.5% increase in revenue to AED454.1 million. EBITDA More… |
